Ventyx Biosciences (VTYX)

• Market cap: $608M
• 1 day: 1.31%
• 5 days: 36.48%
• 1 month: 174.28%
• 3 months: 204.64%
• 6 months: 541.35%
• Year to date: 298.6%
• 1 year: 294.91%
• 5 years: -59.42%
• 10 years: -59.42%
• Sector: Healthcare
• Industry: Biotechnology

About: Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

Employees: 81